Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Improvement in Memory With Plasticity-Based Adaptive Cognitive Training (IMPACT) (IMPACT)

This study has been completed.
Mayo Clinic
University of Southern California
Information provided by (Responsible Party):
Posit Science Corporation Identifier:
First received: January 25, 2006
Last updated: October 29, 2015
Last verified: October 2015
The primary objective of this study is to evaluate the effects of a computer-based training program on the memory and cognitive abilities of mature individuals undergoing healthy aging.

Condition Intervention
Other: Computerized Plasticity-Based Adaptive Cognitive Training
Other: Educational DVDs

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Improvement in Memory With Plasticity-Based Adaptive Cognitive Training (IMPACT)

Resource links provided by NLM:

Further study details as provided by Posit Science Corporation:

Primary Outcome Measures:
  • Cognitive effects of training [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Safety effects of computer-based training [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Enrollment: 487
Study Start Date: January 2006
Study Completion Date: April 2008
Primary Completion Date: April 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Experimental Treatment
Computerized Plasticity-Based Adaptive Cognitive Training
Other: Computerized Plasticity-Based Adaptive Cognitive Training
Other Names:
  • BrainHQ
  • Brain Fitness Program
Active Comparator: Active Control
Educational DVDs
Other: Educational DVDs

Detailed Description:

The computer-based training program is focused on speech reception to strengthen an individual's memory for speech. This type of training program was chosen because speech perception and memory are crucial elements of human communication and losses in this area are often the first signal of overall cognitive decline.

Subjects meeting eligibility criteria and providing written, informed consent are randomized to one of two 40-session, computerized training programs.


Ages Eligible for Study:   65 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Age 65 or older at the time of consent.
  • Mini-Mental State Examination (MMSE) score of 26 or higher.
  • Fluent English speaker. For the purposes of this study, fluency will be defined as living in an English speaking country and attending an English speaking school by the age of six (participants will demonstrate fluency by reading aloud a selected paragraph).
  • Visual capacity adequate to read 14 point type (participants will demonstrate visual capacity by reading aloud a selected sentence).
  • Adequate hearing capacity. (Participants will demonstrate by repeating a series of words spoken by the screening clinician; the words will be spoken while a view of the clinician's mouth is obstructed to prevent lip-reading.)
  • Willing and able to commit to the 6-month time requirement of the entire study period with an emphasis on availability for the 8-10 week computer based training.

Exclusion Criteria:

  • Mini-Mental State Examination (MMSE) score of 25 or lower.
  • Self-report of current diagnosis or history of major neurological illness. Specifically:

    • Alzheimer's disease
    • Parkinson's disease
    • Multiple sclerosis
    • Amyotrophic lateral sclerosis
  • Self-report of current diagnosis or history of psychiatric illness. Specifically:

    • Major depressive disorder
    • Bipolar disorder
    • Schizophrenia
    • Post traumatic stress disorder
    • Obsessive-compulsive disorder
  • Self-reported history of psychiatric hospitalization.
  • History of a stroke, transient ischemic attack (TIA), or traumatic brain injury within the past year; or lifetime history of stroke, TIA, or traumatic brain injury that has left residual expressive or receptive language problems. Traumatic brain injuries include, but are not limited to: concussion with loss of consciousness; head trauma with loss of consciousness; persistent migraines (persistent being defined as a predictable pattern occurring more frequently than every other month); and history of seizure disorder.
  • Fibromyalgia or symptoms of tremor severe enough to prevent the use of a computer mouse or other pointing device. Clinician to observe participant during signature of consent form, during drawing portion of Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) assessment, and to directly ask participant as instructed in the Body Image Ideals Questionnaire (BIQ) to make tremor assessment.
  • Self-report of current substance abuse, including alcoholism.
  • Current use, or use within the past 3 months, of medications with substantial central nervous system (CNS) effects, including acetylcholinesterase inhibitors and medications with either anticholinergic or antidepressant properties.
  • Behaviors during screening or baseline visits that, in the judgment of the screening clinician, are likely to present significant problems for the trainers in the in home setting may be excluded at the discretion of the clinician. Such behaviors include significant uncooperative behavior, significant rudeness or temper management problems, or inappropriate physical conduct.
  • Unable to perform neuropsychological evaluations.
  • Participant is not capable of giving informed consent or is unable to comprehend and/or follow instructions.
  • Participant is enrolled in a concurrent clinical study that could affect the outcome of this study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00283010

United States, California
Posit Science Corporation
San Francisco, California, United States, 94108
Sponsors and Collaborators
Posit Science Corporation
Mayo Clinic
University of Southern California
Principal Investigator: Henry W Mahncke, PhD Posit Science Corporation